Search
Influenza A virus A/Darwin/9/2021 SAN-010 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16916ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.
Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB16918ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals.
Enlicitide
go.drugbank.com/drugs/DB22580ApprovedInvestigational[L63795] Enlicitide is indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), and was studied in … (CORALreef Lipids), and by 59% in patients with HeFH (CORALreef HeFH), with comparable reductions in non-HDL-C and apolipoprotein B.
Maltotetraose
go.drugbank.com/drugs/DB02237ExperimentalCategories: Compounds used in a research, industrial, or household settingZirconium dioxide
go.drugbank.com/drugs/DB16552InvestigationalCategories: Compounds used in a research, industrial, or household settingGlyceraldehyde-3-Phosphate Dehydrogenase
go.drugbank.com/drugs/DB17012ExperimentalCategories: Oxidoreductases Acting on Aldehyde or Oxo Group DonorsTeicoplanin
go.drugbank.com/drugs/DB06149ApprovedInvestigationalWithdrawnAll teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.
Lefamulin
go.drugbank.com/drugs/DB12825Approved[A183206] Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.
Acellular nerve allograft
go.drugbank.com/drugs/DB30293ApprovedInvestigationalOur team is working on the full update, which will be available soon. [L54673,L54668] … Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral